Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Fitos |
Texto Completo: | https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138 |
Resumo: | Medicinal plants and phytotherapics are considered an alternative for the treatment of several diseases. The SUS has 12 phytotherapics standardized in the RENAME: artichoke, mastic, aloe vera, holy cashew, espinheira-santa, devil's claw, guaco, mint, soy isoflavone, plantago, willow and unha-de-gato. The aim of this work was to evaluate the adverse events of these phytotherapics and the possible drug interactions resulting from the use of conventional medicines concomitant with the use of these phytotherapics. The work was carried out through a review of the databases between 1995 and 2020. Medicinal plants and phytotherapics are constituted of chemical compounds, which are mostly responsible for their pharmacological actions. The complexity of these substances increases the possibility of interactions occurring when conventional drugs are used concomitantly. The interactions can be beneficial or unfavorable, since they can increase drug's effect, reduce its effectiveness, result in adverse reactions or not cause changes in the expected effect of the drug. This work emphasizes the importance of considering herbal medicines and phytotherapics with the same importance as synthetic medicines, basing clinical conduct on reliable scientific evidence, recognizing its effectiveness, but also its adverse effects and the possibility of drug interactions making, thus, its use safer and more efficient. |
id |
FIOCRUZ-1_9c98670aeab89d5e8d71ed8bb61c2e60 |
---|---|
oai_identifier_str |
oai:ojs.revistafitos.far.fiocruz.br:article/1138 |
network_acronym_str |
FIOCRUZ-1 |
network_name_str |
Revista Fitos |
repository_id_str |
|
spelling |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicinesInterações medicamentosas entre fitoterápicos padronizados pelo Sistema Único de Saúde e medicamentos convencionaisPhytotherapicsPhytotherapyAdverse eventsDrug interactionsMedicinal plantsUnified Health SystemFitoterápicosFitoterapiaEventos adversosInterações medicamentosasPlantas MedicinaisSistema Único de SaúdeMedicinal plants and phytotherapics are considered an alternative for the treatment of several diseases. The SUS has 12 phytotherapics standardized in the RENAME: artichoke, mastic, aloe vera, holy cashew, espinheira-santa, devil's claw, guaco, mint, soy isoflavone, plantago, willow and unha-de-gato. The aim of this work was to evaluate the adverse events of these phytotherapics and the possible drug interactions resulting from the use of conventional medicines concomitant with the use of these phytotherapics. The work was carried out through a review of the databases between 1995 and 2020. Medicinal plants and phytotherapics are constituted of chemical compounds, which are mostly responsible for their pharmacological actions. The complexity of these substances increases the possibility of interactions occurring when conventional drugs are used concomitantly. The interactions can be beneficial or unfavorable, since they can increase drug's effect, reduce its effectiveness, result in adverse reactions or not cause changes in the expected effect of the drug. This work emphasizes the importance of considering herbal medicines and phytotherapics with the same importance as synthetic medicines, basing clinical conduct on reliable scientific evidence, recognizing its effectiveness, but also its adverse effects and the possibility of drug interactions making, thus, its use safer and more efficient.As plantas medicinais e os fitoterápicos são alternativas para o tratamento de diversas doenças. O Sistema Único de Saúde (SUS) possui 12 fitoterápicos padronizados na Relação Nacional de Medicamentos Essenciais (RENAME): alcachofra, aroeira, babosa, cáscara-sagrada, espinheira-santa, garra-do-diabo, guaco, hortelã, isoflavona-de-soja, plantago, salgueiro e unha-de-gato. O objetivo deste trabalho foi avaliar os eventos adversos destes fitoterápicos e as possíveis interações medicamentosas resultantes do seu uso concomitante com medicamentos convencionais. O trabalho foi realizado por meio de uma revisão narrativa da literatura no período entre 1995 e 2020. As plantas medicinais e/ou os medicamentos fitoterápicos são constituídos de compostos químicos, que em sua maioria são responsáveis pelas suas variadas ações farmacológicas. A composição química complexa aumenta a possibilidade de interações quando medicamentos convencionais são utilizados concomitantemente. As interações podem ser benéficas ou desfavoráveis, podendo potencializar o efeito de fármacos, reduzir a eficácia, resultar em reações adversas ou não alterar o efeito esperado do fármaco. Ressaltou-se a importância de considerar os fitoterápicos/plantas medicinais com a mesma importância que os medicamentos sintéticos, baseando a conduta clínica em evidências científicas confiáveis, reconhecendo sua eficácia, mas também seus efeitos adversos e a possibilidade de interações medicamentosas tornando, assim, seu uso mais seguro e eficaz.Centro de Inovação em Biodiversidade e Saúde - Farmanguinhos/Fiocruz2022-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/htmltext/xmlhttps://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/113810.32712/2446-4775.2022.1138Revista Fitos; Vol. 16 No. 2 (2022); 248-269Revista Fitos; Vol. 16 Núm. 2 (2022); 248-269Revista Fitos; v. 16 n. 2 (2022); 248-2692446-47751808-9569reponame:Revista Fitosinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporhttps://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1058https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1059https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1097Copyright (c) 2022 Revista Fitosinfo:eu-repo/semantics/openAccessRubio, Karina Taciana SantosNascimento, Maria Alice Pereira doMartucci, Maria Elvira Poleti2022-07-15T12:51:23Zoai:ojs.revistafitos.far.fiocruz.br:article/1138Revistahttps://revistafitos.far.fiocruz.br/index.php/revista-fitos/PUBhttp://revistafitos.far.fiocruz.br/index.php/revista-fitos/oairevistafitos@far.fiocruz.br || eugenio.telles@far.fiocruz.br2446-47752446-4775opendoar:2022-07-15T12:51:23Revista Fitos - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.none.fl_str_mv |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines Interações medicamentosas entre fitoterápicos padronizados pelo Sistema Único de Saúde e medicamentos convencionais |
title |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines |
spellingShingle |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines Rubio, Karina Taciana Santos Phytotherapics Phytotherapy Adverse events Drug interactions Medicinal plants Unified Health System Fitoterápicos Fitoterapia Eventos adversos Interações medicamentosas Plantas Medicinais Sistema Único de Saúde |
title_short |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines |
title_full |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines |
title_fullStr |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines |
title_full_unstemmed |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines |
title_sort |
Drug interaction between standardized herbal medicines by the Unified Health System and conventional medicines |
author |
Rubio, Karina Taciana Santos |
author_facet |
Rubio, Karina Taciana Santos Nascimento, Maria Alice Pereira do Martucci, Maria Elvira Poleti |
author_role |
author |
author2 |
Nascimento, Maria Alice Pereira do Martucci, Maria Elvira Poleti |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Rubio, Karina Taciana Santos Nascimento, Maria Alice Pereira do Martucci, Maria Elvira Poleti |
dc.subject.por.fl_str_mv |
Phytotherapics Phytotherapy Adverse events Drug interactions Medicinal plants Unified Health System Fitoterápicos Fitoterapia Eventos adversos Interações medicamentosas Plantas Medicinais Sistema Único de Saúde |
topic |
Phytotherapics Phytotherapy Adverse events Drug interactions Medicinal plants Unified Health System Fitoterápicos Fitoterapia Eventos adversos Interações medicamentosas Plantas Medicinais Sistema Único de Saúde |
description |
Medicinal plants and phytotherapics are considered an alternative for the treatment of several diseases. The SUS has 12 phytotherapics standardized in the RENAME: artichoke, mastic, aloe vera, holy cashew, espinheira-santa, devil's claw, guaco, mint, soy isoflavone, plantago, willow and unha-de-gato. The aim of this work was to evaluate the adverse events of these phytotherapics and the possible drug interactions resulting from the use of conventional medicines concomitant with the use of these phytotherapics. The work was carried out through a review of the databases between 1995 and 2020. Medicinal plants and phytotherapics are constituted of chemical compounds, which are mostly responsible for their pharmacological actions. The complexity of these substances increases the possibility of interactions occurring when conventional drugs are used concomitantly. The interactions can be beneficial or unfavorable, since they can increase drug's effect, reduce its effectiveness, result in adverse reactions or not cause changes in the expected effect of the drug. This work emphasizes the importance of considering herbal medicines and phytotherapics with the same importance as synthetic medicines, basing clinical conduct on reliable scientific evidence, recognizing its effectiveness, but also its adverse effects and the possibility of drug interactions making, thus, its use safer and more efficient. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-06-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138 10.32712/2446-4775.2022.1138 |
url |
https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138 |
identifier_str_mv |
10.32712/2446-4775.2022.1138 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1058 https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1059 https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1138/1097 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2022 Revista Fitos info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2022 Revista Fitos |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/html text/xml |
dc.publisher.none.fl_str_mv |
Centro de Inovação em Biodiversidade e Saúde - Farmanguinhos/Fiocruz |
publisher.none.fl_str_mv |
Centro de Inovação em Biodiversidade e Saúde - Farmanguinhos/Fiocruz |
dc.source.none.fl_str_mv |
Revista Fitos; Vol. 16 No. 2 (2022); 248-269 Revista Fitos; Vol. 16 Núm. 2 (2022); 248-269 Revista Fitos; v. 16 n. 2 (2022); 248-269 2446-4775 1808-9569 reponame:Revista Fitos instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Revista Fitos |
collection |
Revista Fitos |
repository.name.fl_str_mv |
Revista Fitos - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
revistafitos@far.fiocruz.br || eugenio.telles@far.fiocruz.br |
_version_ |
1798313475582197760 |